Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 159

Sort by

Sort Order Select

Journal Articles

Kinetics of Immune Reconstitution after CD19 CAR-T Cell Therapy in ALL Patients

Ying Wang, Jiang Cao, MD, Yan Zhiling, MD, Jianlin Qiao, PhD, Deipeng Li, MD, Zhenyu Li, MD, Kailin Xu, MD

Blood (2019) 134 (Supplement_1): 1301.

https://doi.org/10.1182/blood-2019-127808

Published: 2019

Journal Articles

Allogeneic Anti-Bcma CAR-T Cells Show Tumour Specific Killing Against Primary Multiple Myeloma Cells from Different Genomic Sub-Groups

Ana M Metelo, PhD, Ieuan Walker, BSc, MSc, MBBS, Agnieszka Jozwik, PhD, Charlotte Graham, MRCP, BSc, MBBS, Charlotte Attwood, BMedSci, MBBS, MRCP, FRCPath, Katy Sanchez, BSc, MSc, Alan Dunlop, BSc, MSc, Kirsty Cuthill, FRCPath,MBBS,MRCP,PhD, Carmel Rice, FRACP, FRCPA, MBBS, Matthew Streetly, MD, Trevor Bentley, BSc, Bijan Boldajipour, PhD, Cesar Sommer, PhD, Barbra Sasu, PhD, Reuben Benjamin, FRCPath, MRCP, MBBS, PhD

Blood (2019) 134 (Supplement_1): 1834.

https://doi.org/10.1182/blood-2019-124312

Published: 2019

Journal Articles

Mechanistic Insights into the Inhibition of T Regulatory Cells By Dasatinib May Predict Immunostimulatory Effects in CML Patients

Patrick Harrington, MRCP, FRCPath, Richard Dillon, MA, PhD MRCP, FRCPath, Philippe Rousselot, MD PhD, Deepti Radia, Yvonne Francis, Claire N Harrison, Professor, Shahram Kordasti, MD PhD, Hugues De Lavallade

Blood (2019) 134 (Supplement_1): 1635.

https://doi.org/10.1182/blood-2019-129135

Published: 2019

Journal Articles

Influence of CD27 - CD28 - T-Cells on the Therapeutic Outcome in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma after CART-Infusion

Nina Worel, MD, Katharina Pfistershammer, Winfried Pickl, Marion Heinz, RN, MPhil, Martina Schlager, Beate Pribitzer, Andreas Tanzmann, MD, Ulrich Jaeger, MD, Georg Hopfinger

Blood (2019) 134 (Supplement_1): 1935.

https://doi.org/10.1182/blood-2019-126191

Published: 2019

Journal Articles

Immunological Consequences of Lenalidomide with and without Dexamethasone in Newly Diagnosed Multiple Myeloma

Jake A. Kloeber, Teresa K. Kimlinger, Jessica L. Haug, Kimberly J. Henderson, S.Vincent Rajkumar, MD, Shaji K. Kumar, MD

Blood (2019) 134 (Supplement_1): 3070.

https://doi.org/10.1182/blood-2019-128335

Published: 2019

Journal Articles

Cellular Kinetics and Anti-Therapeutic Antibody in Relapsed/Refractory B-NHL Patients Treated with JWCAR029

Zhitao Ying, MD PhD, Pengpeng Xu, MD, Ming Hao, PhD, Li Wang, MD PhD, Shu Cheng, MD PhD, Wen Wu, MD PhD, Wen Wang, MD PhD, Zisong Zhou, Su Yang, Jennifer Wang, PhD, Harry Lam, PhD, James Li, Hongxia Zheng, MD PhD, Weili Zhao, MD PhD, Yuqin Song, MD PhD, Jun Zhu, BS

Blood (2019) 134 (Supplement_1): 4083.

https://doi.org/10.1182/blood-2019-126408

Published: 2019

Journal Articles

The Immune Micro-Environment in Diffuse Large B Cell Lymphoma Is Characterised By an Immunosuppressive Shift in T Cell Subsets

Edward Truelove, MBBS, BSc, MRCP, FRCPath, Frances Seymour, MRCP, BSc, MBBS, Joseph G Taylor, MBBS, BSc, Mariarita Calaminici, Andrew James Clear, BSc, John G. Gribben, MD DSc

Blood (2019) 134 (Supplement_1): 5240.

https://doi.org/10.1182/blood-2019-130712

Published: 2019

Journal Articles

Local Manufacture of CD19 CAR-T Cells Using an Automated Closed-System: Robust Manufacturing and High Clinical Efficacy with Low Toxicities

Blood (2019) 134 (Supplement_1): 2625.

https://doi.org/10.1182/blood-2019-130370

Published: 2019

Journal Articles

In Vitro -Selected Nanobody-Based Cellular Therapy Targeting CD72 for Treatment of Refractory B-Cell Malignancies

Matthew Nix, PhD, Yu-Hsiu T. Lin, BA, Huimin Geng, PhD, Makeba Marcoulis, BA, Paul Phojanakong, BA, Donghui Wang, BA, Veronica Steri, PhD, Jeffrey Whitman, MD, Sagar Bapat, MD PhD, Elliot Stieglitz, MD, Anne Deucher, MD PhD, Kristie L White, MD MD, Byron C Hann, MD PhD, Arun P. Wiita, MD PhD

Blood (2019) 134 (Supplement_1): 1337.

https://doi.org/10.1182/blood-2019-130938

Published: 2019

Journal Articles

Single-Cell Mass Cytometry Identifies Mechanisms of Resistance to Immunotherapy in AML

Shelley Herbrich, MS, Antonio Cavazos, Cora Marie C Cheung, BSN, Lynette Alexander-Williams, Nicholas J. Short, MD, Jairo Matthews, Naval G. Daver, MD, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 1428.

https://doi.org/10.1182/blood-2019-128601

Published: 2019

Journal Articles

Translational Analysis from CARTITUDE-1, an Ongoing Phase 1b/2 Study of JNJ-4528 BCMA-targeted CAR-T Cell Therapy in Relapsed and/or Refractory Multiple Myeloma (R/R MM), Indicates Preferential Expansion of CD8+ T Cell Central Memory Cell Subset

Enrique Zudaire, PhD, Deepu Madduri, MD, Saad Z. Usmani, MD FACP, Andrzej Jakubowiak, MD PhD, Jesus G. Berdeja, MD, Dong Geng, Syed Rizvi, MD, Tonia Nesheiwat, Jordan M Schecter, MD, Jenna D. Goldberg, MD, Arnob Banerjee, MD, Alicia J. Allred, PhD, Indrajeet Singh, PhD, Raluca Verona, PhD, Ian McCaffery, PhD, Sundar Jagannath

Blood (2019) 134 (Supplement_1): 928.

https://doi.org/10.1182/blood-2019-127309

Published: 2019

Journal Articles

Allogeneic Anti-CD19 CAR T Cells Manufactured from Healthy Donors Provide a Unique Cellular Product with Distinct Phenotypic Characteristics Compared to CAR T Cells Generated from Patients with Mature B Cell Malignancies

Charlotte Graham, MRCP, BSc, MBBS, Agnieszka Jozwik, PhD, Ruby Quartey-Papafio, Nikolaos Ioannou, PhD MSc, BSc, Ana M Metelo, PhD, Carlo Scala, PhD, Glenda Dickson, PhD, Orla Stewart, Maria Almena-Carrasco, Elisa Peranzoni, Alan G. Ramsay, BSc,MSc,PhD, Sandra Dupouy, Pharm.D, PhD, Farzin Farzaneh, PhD, Piers E.M. Patten, BSc, MRCP, MRCPath, PhD, Andrea Pepper, PhD, Reuben Benjamin, FRCPath, MRCP, MBBS, PhD

Blood (2019) 134 (Supplement_1): 3228.

https://doi.org/10.1182/blood-2019-123018

Published: 2019

Journal Articles

Exploring LAG-3 Expression in Multiple Myeloma Patients Following Autologous Stem Cell Transplant

Lucas Fabienne, PhD, Michael Pennell, PhD, Don M. Benson, Jr., MD PhD, Yvonne Efebera, MD, Maria Chaudhry, MD, Jennifer A. Woyach, MD, Xiangnan Guan, Zhang Suohui, Christin E Burd, PhD, Ashley E. Rosko, MD

Blood (2018) 132 (Supplement 1): 3434.

https://doi.org/10.1182/blood-2018-99-119577

Published: 2018

Journal Articles

Predictors of T Cell Expansion and Clinical Responses Following B-Cell Maturation Antigen-Specific Chimeric Antigen Receptor T Cell Therapy (CART-BCMA) for Relapsed/Refractory Multiple Myeloma (MM)

Adam D. Cohen, MD, J. Joseph Melenhorst, PhD, Alfred L. Garfall, MD, Simon F Lacey, PhD BS, Megan Davis, PhD, Dan T. Vogl, MD, Lifeng Tian, PhD, Vanessa Gonzalez, Iulian Pruteanu, PhD, Anne Marie Nelson, Gabriela Plesa, MD, Adam Waxman, MD, Regina M Young, PhD, Bruce L Levine, PhD, Carl H June, MD, Edward A. Stadtmauer, MD FACP, Michael C. Milone, MD PhD

Blood (2018) 132 (Supplement 1): 1974.

https://doi.org/10.1182/blood-2018-99-119665

Published: 2018

Journal Articles

Abbreviated T-Cell Activation on the Automated Clinimacs Prodigy Device Enhances Bispecific CD19/22 Chimeric Antigen Receptor T-Cell Viability and Fold Expansion, Reducing Total Culture Duration

Sandeep K Srivastava, PhD, Sandhya R. Panch, MD MPH, Jianjian Jin, PhD, Haneen Shalabi, DO, Nirali N. Shah, MD, Steven L Highfill, PhD, David F. Stroncek

Blood (2018) 132 (Supplement 1): 4551.

https://doi.org/10.1182/blood-2018-99-116846

Published: 2018

Journal Articles

Point-of-Care Manufacturing of CD20.19 Bi-Specific Chimeric Antigen Receptor T (CAR-T) Cells in a Standard Academic Cell Processing Facility for a Phase I Clinical Trial in Relapsed, Refractory NHL

Fenlu Zhu, PhD, Nirav N Shah, MD, Dina Schneider, PhD, Huiqing Xu, MD, Katherine Chaney, MS, Lawrence Luib, MS, Carolyn A. Keever-Taylor, DPhil, Boro Dropulic, PhD, Rimas Orentas, PhD, Parameswaran Hari, MBBS, MD, Bryon Johnson, PhD

Blood (2018) 132 (Supplement 1): 4553.

https://doi.org/10.1182/blood-2018-99-116566

Published: 2018

Journal Articles

Title Point-of-Care Production of CD19 CAR-T Cells in an Automated Closed-System: Report of First Clinical Experience

Olga Molostova, MD, Larisa Shelikhova, MD, Yakov Muzalevsky, Alexey Kazachenok, Dmitriy Pershin, Elena Kurnikova, Alexander Popov, MD PhD, Boro Dropulic, PhD, Dina Shneider, Rimas Orentas, PhD, Regina Alex, Mike Essl, Natalia Miakova, MD PhD, Dmitry Litvinov, MD PhD, Alexander Karachunskiy, MD PhD, Galina Novichkova, MD PhD, Alexey A. Maschan, MD, Michael Maschan, MD PhD

Blood (2018) 132 (Supplement 1): 5202.

https://doi.org/10.1182/blood-2018-99-118282

Published: 2018

Journal Articles

Characterization of Allogeneic T Cells Expressing Inducible Caspase-9 Following Adoptive Transfer in Children Receiving an HLA-Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Myeloid Malignancies

Joanne Shaw, PhD, Xiaoou Zhou, MD PhD, An Lu, Valentina Bertaina, Daria Pagliara, MD PhD, Melissa Aldinger, PharmD, David M. Spencer, PhD, Franco Locatelli, Aaron Foster, PhD

Blood (2018) 132 (Supplement 1): 4534.

https://doi.org/10.1182/blood-2018-99-119779

Published: 2018

Journal Articles

Exhausted CLL T Cells Mediated By PD1 Expression an Important Mechanism for CD19 CAR Efficacy in CLL in the Adoptive Transfer TCL1 Mouse Model

Robin Sanderson, MRCP, FRCPath, Arantxa Romero-Toledo, MSc, John G. Gribben

Blood (2018) 132 (Supplement 1): 4537.

https://doi.org/10.1182/blood-2018-99-111180

Published: 2018

Journal Articles

Recovery of Specific Subsets of Natural Killer and T Cells Highly Associated with Graft-Versus-Host Disease after Haploidentical Stem Cell Transplantation in Acute Leukemia

Jieun Jang, MD, Haerim Chung, MD, Yu Ri Kim, MD, Hoi-kyung Jeung, Ju-In Eom, So-Young Seol, Soo-Jeong Kim, MD, Jin Seok Kim, MD, PhD, June-Won Cheong, MD PhD, Yoo Hong Min, MD PhD

Blood (2018) 132 (Supplement 1): 4581.

https://doi.org/10.1182/blood-2018-99-115786

Published: 2018

NARROW

Kinetics of Immune Reconstitution after CD19 CAR-T Cell Therapy in ALL Patients

Allogeneic Anti-Bcma CAR-T Cells Show Tumour Specific Killing Against Primary Multiple Myeloma Cells from Different Genomic Sub-Groups

Mechanistic Insights into the Inhibition of T Regulatory Cells By Dasatinib May Predict Immunostimulatory Effects in CML Patients

Influence of CD27 - CD28 - T-Cells on the Therapeutic Outcome in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma after CART-Infusion

Immunological Consequences of Lenalidomide with and without Dexamethasone in Newly Diagnosed Multiple Myeloma

Cellular Kinetics and Anti-Therapeutic Antibody in Relapsed/Refractory B-NHL Patients Treated with JWCAR029

The Immune Micro-Environment in Diffuse Large B Cell Lymphoma Is Characterised By an Immunosuppressive Shift in T Cell Subsets

Local Manufacture of CD19 CAR-T Cells Using an Automated Closed-System: Robust Manufacturing and High Clinical Efficacy with Low Toxicities

In Vitro -Selected Nanobody-Based Cellular Therapy Targeting CD72 for Treatment of Refractory B-Cell Malignancies

Single-Cell Mass Cytometry Identifies Mechanisms of Resistance to Immunotherapy in AML

Translational Analysis from CARTITUDE-1, an Ongoing Phase 1b/2 Study of JNJ-4528 BCMA-targeted CAR-T Cell Therapy in Relapsed and/or Refractory Multiple Myeloma (R/R MM), Indicates Preferential Expansion of CD8+ T Cell Central Memory Cell Subset

Allogeneic Anti-CD19 CAR T Cells Manufactured from Healthy Donors Provide a Unique Cellular Product with Distinct Phenotypic Characteristics Compared to CAR T Cells Generated from Patients with Mature B Cell Malignancies

Exploring LAG-3 Expression in Multiple Myeloma Patients Following Autologous Stem Cell Transplant

Predictors of T Cell Expansion and Clinical Responses Following B-Cell Maturation Antigen-Specific Chimeric Antigen Receptor T Cell Therapy (CART-BCMA) for Relapsed/Refractory Multiple Myeloma (MM)

Abbreviated T-Cell Activation on the Automated Clinimacs Prodigy Device Enhances Bispecific CD19/22 Chimeric Antigen Receptor T-Cell Viability and Fold Expansion, Reducing Total Culture Duration

Point-of-Care Manufacturing of CD20.19 Bi-Specific Chimeric Antigen Receptor T (CAR-T) Cells in a Standard Academic Cell Processing Facility for a Phase I Clinical Trial in Relapsed, Refractory NHL

Title Point-of-Care Production of CD19 CAR-T Cells in an Automated Closed-System: Report of First Clinical Experience

Characterization of Allogeneic T Cells Expressing Inducible Caspase-9 Following Adoptive Transfer in Children Receiving an HLA-Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Myeloid Malignancies

Exhausted CLL T Cells Mediated By PD1 Expression an Important Mechanism for CD19 CAR Efficacy in CLL in the Adoptive Transfer TCL1 Mouse Model

Recovery of Specific Subsets of Natural Killer and T Cells Highly Associated with Graft-Versus-Host Disease after Haploidentical Stem Cell Transplantation in Acute Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only